Phase II Study of FOLFIRINOX Alternated with Biweekly Gemcitabine Plus Nab-Paclitaxel in Patients with Untreated Metastatic Adenocarcinoma
The purpose of this phase II trial is to evaluate the safety and efficacy of modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel as a combined first-line therapy in patients with metastatic pancreatic cancer.
Study ID: Pro2020002395
Trial Phase: Phase II
Trial Sponsor: Lyudmyla Berim
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, FOLFIRINOX